June 15, 2022

Batavia Biosciences increases capacity for viral vectors and vaccine R&D in Netherlands

Leiden, The Netherlands, June 14, 2022 – Today, Batavia Biosciences announces the expansion of its headquarters and R&D capacities in the Netherlands. The infrastructure increases capacity with another 22,500 sq. ft., firmly demonstrating the company’s commitment to act as pacemakers within the rapidly growing biopharmaceutical market.

The expansion allows the company to increase its R&D activities for viral vector-based product development including Lentivirus, AAV, Adenovirus, and Measles virus vectors. In addition, the increased R&D infrastructure helps to meet increased global demand for vaccine development, be it live-attenuated, whole killed, vectored, or subunit vaccines. The expansion will be finalized by June 2023.

Menzo Havenga, CEO of Batavia Biosciences, states, “At Batavia, we are reminded daily of the urgency of bringing medicines to patients in need. With this infrastructure expansion, our contribution of award-winning process development and clinical manufacturing of vaccines and vector-based products can continue its ascent to new heights. No doubt this will further enable us getting the necessary medicines and therapies into the patients’ hands faster and make them more affordable.”

Chris Yallop, CSO at Batavia Biosciences, adds, “The new laboratory floor space for R&D and analytical capabilities will aid the development capacity for customer projects. The increased allocation for R&D capacity better positions Batavia Biosciences to serve as pacemakers to the community and to continue to bring promising candidate biopharmaceuticals from bench to clinic.”

 Source: Batavia Biosciences
Did you know? We are host to a whopping 515 Medical Specialists